The influence of PRNP polymorphisms on human prion disease susceptibility: an update
- 1.2k Downloads
Two normally occurring polymorphisms of the human PRNP gene, methionine (M)/valine (V) at codon 129 and glutamic acid (E)/lysine (K) at codon 219, can affect the susceptibility to prion diseases. It has long been recognized that 129M/M homozygotes are overrepresented in sporadic Creutzfeldt–Jakob disease (CJD) patients and variant CJD patients, whereas 219E/K heterozygotes are absent in sporadic CJD patients. In addition to these pioneering findings, recent progress in experimental transmission studies and worldwide surveillance of prion diseases have identified novel relationships between the PRNP polymorphisms and the prion disease susceptibility. For example, although 219E/K heterozygosity confers resistance against the development of sporadic CJD, this genotype is not entirely protective against acquired forms (iatrogenic CJD and variant CJD) or genetic forms (genetic CJD and Gerstmann–Sträussler–Scheinker syndrome) of prion diseases. In addition, 129M/V heterozygotes predispose to genetic CJD caused by a pathogenic PRNP mutation at codon 180. These findings show that the effects of the PRNP polymorphisms may be more complicated than previously thought. This review aims to summarize recent advances in our knowledge about the influence of the PRNP polymorphisms on the prion disease susceptibility.
KeywordsCreutzfeldt–Jakob disease Prion PRNP Polymorphism
We thank members of the Creutzfeldt–Jakob Disease Surveillance Committee in Japan, Creutzfeldt–Jakob disease specialists in the prefectures, and Creutzfeldt–Jakob disease patients and families for providing important clinical information. We thank Y. Ishikawa, H. Kudo, M. Yamamoto, and A. Yamazaki for their excellent technical assistance, and B. Bell for critical review of the manuscript. This study was supported by Grants-in-Aid from the Ministry of Health, Labor and Welfare of Japan (A.K., Y.N., M.Y., H.M., S.M. and T.K.), Grants-in-Aid for Scientific Research from JSPS (A.K. and T.K.), the Platform for Drug Design, Informatics, and Structural Lifescience (PDIS) (T.S.), a grant from MEXT for the Joint Research Program of the Research Center for Zoonosis Control, Hokkaido University (T.K.), and a Grant-in-Aid for Scientific Research on Innovative Areas from MEXT (T.K.).
Conflict of interest
The authors declare that they have no conflicting interest.
- 12.Colby DW, Prusiner SB (2011) Prions. Cold Spring Harb Perspect. Biol 3:a006833Google Scholar
- 15.Delisle MB, Fabre N, Rochiccioli P, Doerr-Schott J, Rumeau JL, Bes A (1993) Creutzfeldt–Jakob disease after treatment with human extracted growth hormone. A clinicopathological study. Rev Neurol (Paris) 149:524–527Google Scholar
- 27.Health Protection Agency (2007) Fourth case of transfusion-associated variant-CJD infection. Health Protection Report 1Google Scholar
- 30.Hosszu LL, Jackson GS, Trevitt CR, Jones S, Batchelor M, Bhelt D et al (2004) The residue 129 polymorphism in human prion protein does not confer susceptibility to Creutzfeldt–Jakob disease by altering the structure or global stability of PrPC. J Biol Chem 279:28515–28521PubMedCrossRefGoogle Scholar
- 60.Parchi P, Cescatti M, Notari S, Schulz-Schaeffer WJ, Capellari S, Giese A et al (2010) Agent strain variation in human prion disease: insights from a molecular and pathological review of the National Institutes of Health series of experimentally transmitted disease. Brain 133:3030–3042PubMedCentralPubMedCrossRefGoogle Scholar